← Back to Screener
Castle Biosciences, Inc. Common Stock (CSTL)
Price$25.05
Favorite Metrics
Price vs S&P 500 (26W)-0.21%
Price vs S&P 500 (4W)-9.29%
Market Capitalization$744.77M
P/E Ratio (Annual)47.31x
All Metrics
P/CF (Annual)11.57x
Book Value / Share (Quarterly)$15.86
P/TBV (Annual)2.97x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)35.95%
Cash Flow / Share (Quarterly)$0.95
Price vs S&P 500 (YTD)-39.74%
Gross Margin (TTM)79.37%
Net Profit Margin (TTM)-7.02%
EPS (TTM)$-0.85
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-0.85
Revenue Growth (5Y)40.62%
EPS (Annual)$-0.83
ROI (Annual)-5.02%
Gross Margin (Annual)79.37%
Net Profit Margin (5Y Avg)-21.98%
Cash / Share (Quarterly)$10.09
Revenue Growth QoQ (YoY)0.81%
EPS Growth (5Y)15.01%
P/E Normalized (Annual)47.31x
ROA (Last FY)-4.18%
Revenue Growth TTM (YoY)3.66%
EBITD / Share (TTM)$-0.20
ROE (5Y Avg)-8.05%
Operating Margin (TTM)-12.44%
Cash Flow / Share (Annual)$0.95
P/B Ratio1.58x
P/B Ratio (Quarterly)2.41x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.85x
Net Interest Coverage (TTM)-3.43x
ROA (TTM)-4.42%
EV / EBITDA (TTM)153.16x
EPS Incl Extra (Annual)$-0.83
Current Ratio (Annual)5.26x
Quick Ratio (Quarterly)4.99x
3-Month Avg Trading Volume0.38M
52-Week Price Return17.83%
EV / Free Cash Flow (Annual)22.54x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$12.87
P/S Ratio (Annual)2.16x
Asset Turnover (Annual)0.59x
52-Week High$44.28
Operating Margin (5Y Avg)-27.32%
EPS Excl Extra (Annual)$-0.83
CapEx CAGR (5Y)49.96%
Tangible BV CAGR (5Y)35.03%
26-Week Price Return8.54%
Quick Ratio (Annual)4.99x
13-Week Price Return-38.56%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)5.26x
Enterprise Value$638.511
Revenue / Share Growth (5Y)29.09%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)-1.10%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.73x
Pretax Margin (Annual)-8.57%
Cash / Share (Annual)$10.09
3-Month Return Std Dev49.81%
Gross Margin (5Y Avg)80.12%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)17.49%
ROE (Last FY)-5.13%
Net Interest Coverage (Annual)-3.50x
EPS Basic Excl Extra (Annual)$-0.83
P/FCF (TTM)19.05x
Receivables Turnover (TTM)7.28x
EV / Free Cash Flow (TTM)22.54x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.85
Receivables Turnover (Annual)7.28x
ROI (TTM)-5.15%
P/S Ratio (TTM)2.16x
Pretax Margin (5Y Avg)-24.20%
Revenue / Share (Annual)$11.88
Tangible BV / Share (Annual)$12.87
Free OCF CAGR (5Y)40.79%
Price vs S&P 500 (52W)-17.27%
Year-to-Date Return-35.60%
5-Day Price Return6.46%
EPS Normalized (Annual)$-0.83
ROA (5Y Avg)-7.04%
Net Profit Margin (Annual)-7.02%
Month-to-Date Return2.04%
Cash Flow / Share (TTM)$-2.39
EBITD / Share (Annual)$-0.20
Operating Margin (Annual)-12.44%
LT Debt / Equity (Annual)0.02x
P/CF (TTM)11.57x
ROI (5Y Avg)-8.04%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-0.85
P/TBV (Quarterly)2.97x
P/B Ratio (Annual)2.41x
Inventory Turnover (TTM)7.73x
Pretax Margin (TTM)-8.57%
Book Value / Share (Annual)$15.86
Price vs S&P 500 (13W)-41.42%
Net Margin Growth (5Y)-11.67%
Beta1.17x
P/FCF (Annual)26.29x
Revenue / Share (TTM)$11.73
ROE (TTM)-5.27%
52-Week Low$14.59
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.43
4.38
4.43
4.43
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
CSTLCastle Biosciences, Inc. Common Stock | 47.31x | 3.66% | -12.44% | -5.27% | $25.05 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $208.40 |
LHLabcorp Holdings Inc. | 25.45x | 7.25% | 9.92% | 10.28% | $270.68 |
DGXQuest Diagnostics Inc. | 21.60x | 11.78% | 14.10% | 13.88% | $195.02 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $90.36 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.39 |
VCYTVeracyte, Inc. | 40.48x | 16.01% | 11.17% | 5.33% | $33.80 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.71 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.42 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.38 |
About
Castle Biosciences is a molecular diagnostics company specializing in gene expression profile tests for oncology and gastrointestinal conditions. Its product portfolio includes DecisionDx-Melanoma and DecisionDx-SCC for skin cancer risk assessment, MyPath Melanoma for melanoma diagnosis, and TissueCypher for monitoring esophageal cancer progression. The company generates revenue by delivering diagnostic test reports to healthcare providers treating patients with dermatologic cancers, uveal melanoma, and Barrett's esophagus.